Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

87.89 +6.63 (+8.16%)
Streaming Delayed Price Updated: 2:35 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 Next >
Belite Bio to Participate in the 2025 Maxim Growth Summit
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in Three Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Registered Direct Offering of $15 Million
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Registered Direct Offering of $15 Million
From Belite Bio, Inc
Via GlobeNewswire
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
From Lin BioScience, Inc.
Via GlobeNewswire
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
From Belite Bio, Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.